Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.
Lévy Y, Lacabaratz C, Ellefsen-Lavoie K, Stöhr W, Lelièvre JD, Bart PA, Launay O, Weber J, Salzberger B, Wiedemann A, Surenaud M, Koelle DM, Wolf H, Wagner R, Rieux V, Montefiori DC, Yates NL, Tomaras GD, Gottardo R, Mayer B, Ding S, Thiébaut R, McCormack S, Chêne G, Pantaleo G.
Lévy Y, et al. Among authors: rieux v.
PLoS Pathog. 2020 Jun 26;16(6):e1008522. doi: 10.1371/journal.ppat.1008522. eCollection 2020 Jun.
PLoS Pathog. 2020.
PMID: 32589686
Free PMC article.
Clinical Trial.